



March 25, 2016

AnGes MG, Inc.

## **Summary of the Announcement Regarding the Issue of Stock Acquisition Rights**

The 27th Series of Stock Acquisition Rights  
(Private Placement) (with Option to Revise Exercise Price)

AnGes MG Inc. ("AnGes") announced on March 25, 2016, that it will issue stock acquisition rights to Mita Securities Co., Ltd. The following is a summary of the announcement.

- The number of stock acquisition rights: 64,367 (6,436,700 shares)
- Allotment date: April 11, 2016
- Exercise period: April 12, 2016 to April 11, 2017
- Initial exercise price: JPY 435 (92% of the closing price of March 24, 2016)
- Minimum exercise price: JPY 236 (50% of the closing price of March 24, 2016)
- Maximum exercise price: N/A
- The exercise price is to be adjusted at 92% of the closing price of Friday every week. The exercise price will not be revised below the minimum exercise price of JPY 236.

AnGes plans to apply the proceeds from the exercise of stock acquisition rights primarily towards development costs in connection with NF-kB Decoy Oligonucleotide for atopic dermatitis (including costs of Phase 3 clinical trials, chemistry, manufacturing and control costs and other development costs) and in connection with NF-kB Decoy Oligonucleotide for disc degeneration (including costs of Phase 1/2 clinical trials, chemistry, manufacturing and control costs and other development costs).

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
--